Is sotorasib (AMG510) considered a targeted drug? Which generation does it belong to?

Sotoracib (AMG510) is a targeted drug and belongs to the first generation KRAS G12C inhibitor. Targeted drugs refer to drugs that treat cancer by specifically acting on specific molecules or signaling pathways in cancer cells. The development of sotoraxib marks the advent of the first generation KRAS G12C inhibitor. These drugs are highly specific and can selectively act on the KRAS G12C mutation, while having no effect on normal KRAS protein.

Sotorasiib is a drug that targets the KRAS G12C mutation, one of the most common tumor driver gene mutations in humans. KRAS gene mutations are very common in various cancers, especially lung cancer and colorectal cancer. These mutations prevent the KRAS protein from shutting down its activity normally, leading to abnormal cell proliferation and cancer development.

Sotorasiib specifically binds toKRAS G12C mutated protein, inhibits its activity, and blocks signaling pathways related to cell proliferation and survival. The development of this drug is important because KRAS mutations have long been considered a cancer driver gene that is difficult to target and treat. The development and marketing of sotoraxib opens up a new path for targeted treatment of KRAS mutations and provides new hope for patients with KRAS mutations.

Sotorasiib represents a major advance in the field of targeted therapy for KRAS mutations, providing a new treatment option for patients with KRAS mutations, but further research and development is needed. With the continuous deepening of scientific research, more new KRAS G12C inhibitors may be developed in the future, and this type of drugs will be further improved and developed.